Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sugammadex

sugammadex

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sugammadex

67 trials tracked of sugammadex: 56 in phase 3 or 4 and 22 with published results. The most-cited published study has 380 citations.

67Trials tracked
56Phase 3 & 4
0Recruiting
22With published results
Phase distribution
Phase 4 33 Phase 3 23 Phase 2 6 Phase 1 2 Other / NA 3
  1. Phase 3 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) Completed · 380 cited
  2. Phase 4 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer Completed · 261 cited
  3. Phase 3 Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026) Completed · 242 cited
  4. Phase 3 Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) Completed · 233 cited
  5. Phase 4 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications Completed · 142 cited
  6. Phase 3 Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029) Completed · 121 cited
Show 44 more trials
  1. Phase 3 Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo Completed · 65 cited
  2. Phase 3 Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) Completed · 55 cited
  3. Phase 3 Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028) Completed · 55 cited
  4. Phase 4 Neuromuscular Blockade on Shoulder Pain of Elderly Completed · 28 cited
  5. Phase 4 Deep Neuromuscular Block for Laparoscopic Surgery Completed · 25 cited
  6. Phase 4 Quality of Recovery After Reversal With Neostigmine or Sugammadex. Completed · 20 cited
  7. Phase 4 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery Completed · 18 cited
  8. Phase 4 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Completed · 14 cited
  9. Phase 3 Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient Completed · 8 cited
  10. Phase 4 Sugammadex To IMprove Bowel Function Completed · 3 cited
  11. Phase 4 Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy Completed · 2 cited
  12. Phase 3 Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) Completed · 2 cited
  13. Phase 4 Muscle Relaxation for Pediatric Adenotonsillectomy Completed
  14. Phase 4 Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Completed
  15. Phase 4 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery Completed
  16. Phase 4 Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery Completed
  17. Phase 4 Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile Completed
  18. Phase 4 The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery Completed
  19. Phase 4 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency Completed
  20. Phase 4 Investigation of Sugammadex in Outpatient Urological Procedures Completed
  21. Phase 4 Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade? Completed
  22. Phase 4 Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures Completed
  23. Phase 4 Effect of Neuromuscular Blockade and Reversal on Breathing Completed
  24. Phase 4 Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients Completed
  25. Phase 4 Sugammadex and Decreased Time to Extubation Completed
  26. Phase 4 Sugammadex vs Placebo to Prevent Residual Neuromuscular Block Completed
  27. Phase 4 Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine Completed
  28. Phase 4 Comparison of Time to Extubation Using Sugammadex or Neostigmine Completed
  29. Phase 4 Postoperative Urinary Retention in Patients After Noncardiac Surgery and Reversal of Neuromuscular Block Completed
  30. Phase 4 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications Completed
  31. Phase 4 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy Completed
  32. Phase 4 Sugammadex as Rescue Therapy Completed
  33. Phase 4 Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade Completed
  34. Phase 4 Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex Completed
  35. Phase 4 A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982) Completed
  36. Phase 4 Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients Completed
  37. Phase 3 Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant Completed
  38. Phase 3 The POUR (Postoperative Urinary Retention) Study Completed
  39. Phase 3 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) Completed
  40. Phase 3 Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Completed
  41. Phase 3 Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773) Completed
  42. Phase 3 Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767) Completed
  43. Phase 3 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) Completed
  44. Phase 3 Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) Completed

Showing the 50 most-cited and recently-updated of 67 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sugammadex reduces recovery time after surgery by 6.66 minutes compared to anticholinesterase agents
Gastroenterology Meta-analysis
Sugammadex reduces recovery time after surgery by 6.66 minutes compared to anticholinesterase agents Sugammadex May Help Patients Recover Faster After Surgery
This meta-analysis of 4,082 adult surgical patients compared sugammadex to anticholinesterase agents for neuromuscular blockade reversal. Th…
A review of surgical data suggests that sugammadex may lead to faster neuromuscular recovery and shorter recovery times compared to traditio…
Frontiers Oct 8, 2026
Sugammadex selectively reverses rocuronium blockade within 3 minutes, review reports
Drug Pipeline Sys. Review
Sugammadex selectively reverses rocuronium blockade within 3 minutes, review reports Sugammadex quickly reverses muscle paralysis caused by rocuronium
This narrative review examines sugammadex for reversal of neuromuscular blockade, covering mechanism of action, pharmacokinetics, dosing, ad…
A new way to quickly reverse muscle paralysis during surgery can work in under three minutes, helping patients wake up faster and safer.
Frontiers Sep 17, 2026
General anesthesia with reduced rocuronium and sugammadex reversal safely enabled cesarean section in a patient with inclusion body myositis
Anesthesiology & Pain Medicine Sys. Review
General anesthesia with reduced rocuronium and sugammadex reversal safely enabled cesarean section in a patient with inclusion body myositis A single case shows safe anesthesia for a pregnant patient with inclusion body myositis
This case report describes the perioperative anesthetic management of a 43-year-old pregnant patient with inclusion body myositis undergoing…
A 43-year-old pregnant patient with inclusion body myositis had a cesarean section without complications. Her baby scored 10 out of 10 on Ap…
Frontiers Jun 2, 2026
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients
Diabetes & Endocrinology RCT
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients Sugammadex Helps Obese Patients Breathe Easier
A randomized double-blind controlled trial in 104 morbidly obese patients compared sugammadex (2 mg/kg) with neostigmine+atropine.
This new research shows that a specific reversal drug helps morbidly obese patients breathe better and avoid lung issues after surgery.
Apr 14, 2026